id: tnf_inhibitor_use_to_pneumocystis_jirovecii_infection
name: TNF Inhibitor Use â†’ Pneumocystis jirovecii Infection
from_node:
  node_id: tnf_inhibitor_use
  node_name: TNF Inhibitor Use
to_node:
  node_id: pneumocystis_jirovecii_infection
  node_name: Pneumocystis jirovecii Infection
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: TNF inhibitors reduce the magnitude of innate immune responses in patients
  with autoimmune conditions'
- 'Step 2: Immunosuppression creates vulnerability to opportunistic fungal pathogens'
- 'Step 3: Pneumocystis jirovecii accounts for 20% of all non-viral infections in
  TNF inhibitor recipients'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Ryan Ha et al. 2022. "Increased susceptibility to pneumonia due
    to tumour necrosis factor inhibition and prospective immune system rescue via
    immunotherapy." *Frontiers in Cellular and Infection Microbiology*. https://doi.org/10.3389/fcimb.2022.980868
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:07.080191'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: monoclonal_antibody_type
  direction: strengthens
  strength: strong
  description: Monoclonal antibody-based TNF inhibitors show stronger immunosuppression
    than receptor-based alternatives
- name: concurrent_corticosteroids
  direction: strengthens
  strength: moderate
  description: Combined use of corticosteroids with TNF inhibitors compounds immunosuppressive
    effects
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/biological/tnf_inhibitor_use_to_pneumocystis_jirovecii_infection.yaml
_category: biological
